

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5378434

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	HAMILTON HEALTH SCIENCES CORPORATION	10/31/2018
RECEIVING PARTY DATA		
Name:	BAYER INC.	
Street Address:	77 BELFIELD ROAD, TORONTO	
City:	ONTARIO	
State/Country:	CANADA	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16264032
CORRESPONDENCE DATA		
Fax Number:	(317)592-5453	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	3172362483	
Email:	ipdocket@icemiller.com	
Correspondent Name:	CHRISTINE HANSEN, ICE MILLER LLP	
Address Line 1:	ONE AMERICAN SQUARE, SUITE 2900	
Address Line 4:	INDIANAPOLIS, INDIANA 46282	
ATTORNEY DOCKET NUMBER:	P03727US01 (62983.1139)	
NAME OF SUBMITTER:	CHRISTEN HANSEN	
SIGNATURE:	/Christen Hansen/	
DATE SIGNED:	02/15/2019	
Total Attachments: 1		
source=Bayer_Assignment#page1.tif		

ASSIGNMENT OF INVENTION


WHEREAS, Hamilton Health Sciences Corporation, 237 Barton Street East, Hamilton, Ontario L8L2X2 Canada ("Assignor") entered into an agreement on June 17, 2011 with Bayer Inc., 77 Belfield Road, Toronto, Ontario, Canada ("Assignee") concerning services relating to the COMPASS clinical trial of XARELTO® rivaroxaban ("the Clinical Trial Service Agreement");

WHEREAS, the Clinical Trial Service Agreement provides for the transfer from Assignor to Assignee of ownership of rights to findings, data, test results, discoveries, inventions, processes, methods, techniques, formulae, substances, specifications, materials, documents, studies, designs and improvements whatsoever arising from or relating to the performance of services by Assignor, its directors, officers, employees or Affiliates (as that term is defined in the Clinical Trial Service Agreement) under the Clinical Trial Service Agreement;

Now, therefore, in consideration of the payment by Assignee to Assignor of the sum of one dollar (US\$1.00) and for other good and valuable consideration, the receipt of which is hereby acknowledged, Assignor hereby sells, assigns, and transfers to Assignee, and its successors, assigns and legal representatives, Assignor's entire right, title and interest in and to, including the right to claim priority from, the invention(s) disclosed in U.S. Patent Application No. 62/625,646 filed February 2, 2018 (Confirmation No. 6515) ("the Patent Property"), and in and to all Letters Patent and equivalents thereof to be obtained for said invention(s) in the United States, or any continuation, division, renewal, substitute or equivalent thereof, as well as to any reissue, reexamination, patent term restoration, or equivalent thereto in the United States.

Assignor hereby represents, warrants and covenants that, except for any prior assignments disclosed herein (to the extent executed and delivered by Assignor), no valid assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with assignment of the Patent Property to Assignee, and that Assignee will, upon Assignee's request, be provided promptly with all pertinent facts and documents relating to said invention(s) and said Letters Patent and legal equivalents as may be known and accessible to Assignor, and Assignor will testify as to the same in any interference, litigation or other proceeding related thereto, and will promptly execute and deliver to Assignee or its legal representative(s) any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention(s) and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

IN WITNESS WHEREOF, I/we have hereunto respectively set hand(s) and seal(s) on the date(s) shown below:



printed name: TED SCOTT
capacity: Vice President, Research &
Chief Innovation Officer
for Hamilton Health Sciences Corporation

2018-05-31

Date